Evaluating the Practice of Prescribing Beta-blockers in Compensated Cirrhosis by Gastroenterologists in the Asia Pacific Region.

Autor: Rana R; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India., Sharma S; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India.; Translational Gastroenterology Unit, John Radcliff Hospital, Oxford, United Kingdom., Ahmed S; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India., Gupta A; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India., Jun WY; Department of Gastroenterology & Hepatology, Changi General Hospital, Singhealth, Singapore.; Duke-NUS Medical School, Singapore., Gunjan D; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India., Saraya A; Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, 110029, India.
Jazyk: angličtina
Zdroj: Journal of clinical and experimental hepatology [J Clin Exp Hepatol] 2023 Mar-Apr; Vol. 13 (2), pp. 380-383. Date of Electronic Publication: 2022 Sep 20.
DOI: 10.1016/j.jceh.2022.09.003
Abstrakt: Non-selective beta-blockers (NSBBs) have a role in the management of portal hypertension. They are currently advocated in patients with clinically significant portal hypertension (CSPH) based on Baveno-VII consensus. Current survey aimed to evaluate the practice and perceptions of prescribing NSBBs in portal hypertension by gastroenterologists and hepatologists in Asia-Pacific region in patients with compensated cirrhosis. Out of 1500 gastroenterologists approached in the region, 328 gastroenterologists responded and completed the survey. 75% of the respondents were found not to be following practice of evaluating CSPH as they prescribed NSBBs in patients of compensated cirrhosis with high-risk varices only. Major concerns raised were non-availability of hepatic venous pressure gradient and reliable non-invasive tests as surrogate of CSPH to adapt PREDESCI methodology. While 56.7% used carvedilol as the preferred NSBB to treat patients with compensated cirrhosis, 43.3% used propranolol. This survey assessed the real-world scenario of prescribing NSBBs among practicing gastroenterologists/hepatologists in patients with compensated cirrhosis.
(© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: